Research shows peptides that reduce the viability of prostate cancer cells

We are pleased to share that a study developed by researchers at the University of Aveiro has been highlighted by the University, reporting promising findings on novel experimental peptides with potential relevance for prostate cancer research.

The study shows that bioportides targeting Protein Phosphatase 1 (PP1)—an enzyme implicated in prostate cancer progression and resistance to hormonal therapies—can significantly reduce the viability of prostate cancer cells. This effect was particularly pronounced when peptides were used in combination, suggesting a synergistic action.

Importantly, while a reduction in cell viability was observed, no changes were detected in androgen receptor or PSA expression, indicating that the underlying mechanisms of action remain to be fully elucidated.

This work was conducted by Renato Rodrigues, Juliana Felgueiras, Bárbara Matos, and Margarida Fardilha (University of Aveiro), in collaboration with Vânia Camilo and Cármen Jerónimo (IPO-Porto), and Sarah Jones and John Howl (University of Wolverhampton).

Although further studies are required, these findings open new avenues for exploring bioportides as potential tools in prostate cancer research and therapeutic development.

Read more here: https://www.ua.pt/pt/noticias/9/97656